Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Paramo, J.A. (José Antonio) | - |
| dc.creator | Garcia, R. (R.) | - |
| dc.creator | Rodriguez, P. (P.) | - |
| dc.creator | Panizo, E. (Elena) | - |
| dc.creator | Lecumberri, E. (E.) | - |
| dc.date.accessioned | 2012-07-10T18:59:14Z | - |
| dc.date.available | 2012-07-10T18:59:14Z | - |
| dc.date.issued | 2007 | - |
| dc.identifier.citation | Paramo JA, Garcia R, Rodriguez P, Panizo E, Lecumberri R. Tratamiento del síndrome antifosfolípido. Rev Med Univ Navarra 2007 Oct-Dec;51(4):38-41. | es_ES |
| dc.identifier.issn | 0556-6177 | - |
| dc.identifier.uri | https://hdl.handle.net/10171/22867 | - |
| dc.description.abstract | The antiphospholipid syndrome (APS) is a disorder of recurrent thrombosis and/or pregnancy loss associated with the presence of antiphospholipid antibodies and persistently positive lupus anticoagulant, anticardiolipin or anti beta2-glycoprotein1. Oral anticoagulants are the best available and most effective treatment for the secondary prevention of recurrent venous or arterial thrombosis. Patients with APS are treated with long-term therapy to prolong the INR to 2.0-3.0. Low-molecular-weight heparin in combination with low-aspirin dose is a reasonable strategy to avoid pregnancy loss in women with this syndrome. | es_ES |
| dc.language.iso | spa | es_ES |
| dc.publisher | Ediciones Universidad de Navarra | es_ES |
| dc.rights | info:eu-repo/semantics/openAccess | es_ES |
| dc.subject | Antiphospholipid syndrome | es_ES |
| dc.subject | Thrombosis | es_ES |
| dc.subject | Fetal death | es_ES |
| dc.subject | Lupus anticoagulant | es_ES |
| dc.title | Tratamiento del síndrome antifosfolípido | es_ES |
| dc.type | info:eu-repo/semantics/article | es_ES |
| dc.relation.publisherversion | https://revistas.unav.edu/index.php/revista-de-medicina | es_ES |
| dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.
